Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease

Taliglucerase alfa is an enzyme replacement therapy (ERT) approved for treatment of adult and paediatric patients with Type 1 Gaucher disease (GD) in several countries and the first plant cell–expressed recombinant therapeutic protein approved by the US Food and Drug Administration for humans. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimran, Ari, Wajnrajch, Michael, Hernandez, Betina, Pastores, Gregory M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824466/
https://www.ncbi.nlm.nih.gov/pubmed/29471850
http://dx.doi.org/10.1186/s13023-018-0776-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824466/
https://www.ncbi.nlm.nih.gov/pubmed/29471850
http://dx.doi.org/10.1186/s13023-018-0776-8

Ejemplares similares